Keratosis, Actinic Clinical Trial
Official title:
A Single-center, Open, Randomized, Non-controlled, Comparative Pre-market Investigation to Evaluate the Performance of a Skin Preparation Device for Removal of Hyperkeratotic Skin
Verified date | October 2023 |
Source | Mirka Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In this clinical one-site investigation the performance and safety of a skin preparation device will be evaluated for removing hyperkeratotic skin prior to further medical treatment. Comfort and pain during skin preparation, as well as performance and safety of device, will be compared to comparators on separate skin areas for every subject.
Status | Completed |
Enrollment | 26 |
Est. completion date | September 26, 2023 |
Est. primary completion date | September 26, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: - Attending the clinic for treatment of actinic keratosis using daylight photodynamic therapy - Age: 18 - 100 years. - Available for two follow-up visits: two weeks after treatment and 4 months after treatment - Provision of informed consent i.e., subject must be able to understand and sign the patient Information and Consent Form - Subject have been informed on the nature, the scope and the relevance of the study Exclusion Criteria: - Known or suspected allergy/hypersensitivity to phenol formaldehyde - Wound at the skin site to be treated - Documented skin disease at the time of enrollment, as judged by the investigator - Previously enrolled in the present investigation - Inclusion in other ongoing investigations simultaneously that would preclude the subject from participating in this investigation as judged by the investigator - Actinic keratosis treatment obtained within last 6 months - Involvement in the planning and conduct of the clinical investigation (applies to all investigation site staff and third party vendor) - Any subject that according to Medical Research Act, paragraphs 7-10, is deemed unsuitable for study enrolment. - Complications that would increase wound risks if investigational product would be used. |
Country | Name | City | State |
---|---|---|---|
Finland | Vaasa Central Hospital | Vaasa |
Lead Sponsor | Collaborator |
---|---|
Mirka Ltd | Clinius Ltd |
Finland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Grade of hyperkeratotic skin removal | Sufficient hyperkeratotic skin removal in comparison to comparative methods. The removal of hyperkeratotic skin is assessed visually and by palpation.
Removal of hyperkeratotic skin measurement grades: All hyperkeratotic skin removed, Partial hyperkeratotic skin removed, None hyperkeratotic skin removed. |
Day 0 | |
Secondary | Grade of injury to skin / grade of skin irritation / grade of allergic skin reaction | Investigator assessment of adverse effects on skin in comparison to the comparative methods.
Grade of injury to skin: none, mild, moderate, severe. Grade of skin irritation: none, mild, moderate, severe. Grade of allergic skin reaction: none, mild, moderate, severe. |
Day 0 | |
Secondary | Grade of skin irritation / grade of allergic skin reaction | Investigator assessment of adverse effects on skin in comparison to the comparative methods.
Grade of skin irritation: none, mild, moderate, severe. Grade of allergic skin reaction: none, mild, moderate, severe. |
14 day follow-up | |
Secondary | Duration of operation time per treated skin area | Operation time assessed by the mean difference in time per treated skin area to remove the hyperkeratotic skin in comparison to comparative methods. | Day 0 | |
Secondary | Presence of actinic keratosis | Presence of actinic keratosis (AK) is measured by number of different grades of AK lesions.
Number of different grades of AK lesions: None, Grade I AK lesions, Grade II AK lesions, Grade III AK lesions. |
Day 0 | |
Secondary | Clearance of actinic keratosis | Number of different grades of actinic keratosis (AK) lesions are measured: None, Grade I AK lesions, Grade II AK lesions, Grade III AK lesions.
Actinic keratosis clearance is assessed as the number of cleared actinic keratosis lesions at 4th month follow-up divided by the actinic keratosis lesion number at Day 0. Clearance will be reported in %. A high %-value means a high number of cleared lesions. |
4th month follow-up | |
Secondary | Physician comfort during skin preparation using an investigator questionnaire | Rate of physician comfort when comparing the investigational product versus comparative methods. The endpoint will utilize a questionnaire for the investigator/nurse to fill in. | Day 0 | |
Secondary | Subject comfort during skin preparation using a subject questionnaire | Rate of subject comfort (including skin sensation and heating of skin) when comparing the investigational product with comparative methods. The endpoint will utilize a questionnaire for the subject to fill in.
Skin sensation during skin preparation: Very pleasant, Pleasant, Neutral, Unpleasant, Very unpleasant. Heating of skin during skin preparation: None, Mild temperature rise, Moderate temperature rise, High temperature rise, Burning. |
Day 0 | |
Secondary | Subject pain sensation during skin preparation | Rate of pain using visual analogue scale (VAS). VAS: 0 - 10 (0= No pain and 10 = worst possible pain) | Day 0 | |
Secondary | Subject pain sensation during daylight photodynamic treatment | Rate of pain using visual analogue scale (VAS). VAS: 0 - 10 (0= No pain and 10 = worst possible pain) | Day 0 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03076892 -
Evaluation of Non-inferiority and Tolerability of the Device PHOS-ISTOS
|
N/A | |
Terminated |
NCT03076918 -
Evaluating the Device FLEXITHERALIGHT Compared to the Conventional Photodynamic Therapy
|
N/A | |
Recruiting |
NCT05387525 -
A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp
|
Phase 4 | |
Completed |
NCT02594644 -
The Use of Microneedles to Expedite Treatment Time in Photodynamic Therapy
|
N/A | |
Active, not recruiting |
NCT02281682 -
IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis
|
Phase 4 | |
Completed |
NCT01458587 -
Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)
|
Phase 2 | |
Completed |
NCT05260073 -
Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis
|
||
Active, not recruiting |
NCT06014697 -
OCT and Invasion in Cutaneous Skin Lesions
|
||
Completed |
NCT05279131 -
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
|
Phase 3 | |
Completed |
NCT05481073 -
UV Sensor in Patients With Actinic Keratosis
|
||
Completed |
NCT03697590 -
Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage
|
Phase 4 | |
Withdrawn |
NCT02813902 -
A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors
|
Phase 1 | |
Recruiting |
NCT05636800 -
Microwave Treatment for Actinic Keratosis
|
N/A | |
Completed |
NCT02628236 -
Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)
|
Phase 2 | |
Recruiting |
NCT06135415 -
A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis
|
Phase 3 | |
Completed |
NCT02644187 -
Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol
|
N/A | |
Completed |
NCT02281136 -
MUSE Study of Levulan Kerastick
|
Phase 2 | |
Completed |
NCT05060237 -
Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
|
Phase 1 | |
Terminated |
NCT04269395 -
A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
|
Phase 3 |